Completed PHASE2 INTERVENTIONAL 1-arm NCT02527707

Titrating-Dose of Lonafarnib in Combination With Ritonavir (LOWR-4)

A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of a Titrating-Dose Lonafarnib/Ritonavir in Patients Chronically Infected With Hepatitis Delta Virus

Sponsor: Eiger BioPharmaceuticals

Conditions Chronic Delta Hepatitis

Interventions Ritonavir lonafarnib

Updated 10 times since 2017 Last updated: May 26, 2023 Started: Sep 30, 2015 Primary completion: Aug 31, 2016 Completion: Feb 9, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Delta Hepatitis and is currently completed. Eiger BioPharmaceuticals leads this study, which shows 10 recorded versions since 2015 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jul 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2023 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Apr 2022 — Dec 2022 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eiger BioPharmaceuticals
Hannover Medical School

Data source: Eiger BioPharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.